None
Quote | Protalix BioTherapeutics Inc. (NYSE:PLX)
Last: | $1.10 |
---|---|
Change Percent: | -1.79% |
Open: | $1.12 |
Close: | $1.12 |
High: | $1.13 |
Low: | $1.1 |
Volume: | 119,083 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Protalix BioTherapeutics Inc. (NYSE:PLX)
Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout PR Newswire Event will take place on Wednesday, June 26, 2024 in New York CARMIEL, Israel , J...
Protalix BioTherapeutics to Present at the 2024 BIO International Convention PR Newswire Corporate presentation scheduled for Monday, June 3, 2024 at 2:30 P.M. PDT CARMIEL, Israel , May 29, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc....
Message Board Posts | Protalix BioTherapeutics Inc. (NYSE:PLX)
Subject | By | Source | When |
---|---|---|---|
Most of the payments must be tied to | king oil | investorshub | 05/19/2023 12:37:06 AM |
I remotely recall that Chiesi paid of some | midastouch017 | investorshub | 05/18/2023 4:08:44 PM |
Well that explains the stock plummeting after approval. | king oil | investorshub | 05/18/2023 3:44:12 PM |
On a proforma basis, including the receipt of | midastouch017 | investorshub | 05/18/2023 12:46:17 PM |
Protalix BioTherapeutics Announces $20 Million Milestone Payment from | midastouch017 | investorshub | 05/18/2023 12:40:47 PM |
News, Short Squeeze, Breakout and More Instantly...
Protalix BioTherapeutics Inc. Company Name:
PLX Stock Symbol:
NYSE Market:
Protalix BioTherapeutics Inc. Website:
Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout PR Newswire Event will take place on Wednesday, June 26, 2024 in New York CARMIEL, Israel , J...
Protalix BioTherapeutics to Present at the 2024 BIO International Convention PR Newswire Corporate presentation scheduled for Monday, June 3, 2024 at 2:30 P.M. PDT CARMIEL, Israel , May 29, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc....